| Catalyst | Drug/Treatment | Stage | Probability of Approval | Description | Drug Type | Therapeutic Area | Source |
|---|---|---|---|---|---|---|---|
PDUFA 2026 | Phase 3 | -% | FDA review of the new drug application for the treatment of example condition. Read More | Small Molecule | Oncology | ||
PDUFA 2026 | Phase 3 | -% | FDA review of the new drug application for the treatment of example condition. Read More | Small Molecule | Oncology | ||
PDUFA 2026 | Phase 3 | -% | FDA review of the new drug application for the treatment of example condition. Read More | Small Molecule | Oncology |
Recent Updates
Recently added Catalysts
MiniMed Group, Inc.$15.29
-0.3 (-1.92%)
C 59Pipeline Score MedTech · Commercial
Market Cap
3.33 B
EPS
-
P/E Ratio
-
Value Trade
41.85 M
SEC Financials
Q2 2026Dilution Risk
Revenue
3.10 B
R&D Expenses
448.00 M
Operating CF
-197.00 M
Total Assets
4.63 B
Total Liabilities
1.02 B
Equity
3.61 B
D/E Ratio
12,345
7.91 %
Week
-11.48 %
1 Month
-35.84 %
3 Month
-35.84 %
6 Month
-35.84 %
5 Year
-35.84 %
All Time
Cash Data
Cash Position
373.00 M
Monthly Burn
16.42 M
Runway
22.5 mo
Burn Trend
SEC Filing
Jun 29, 2026
Overview
Volume
1.03 M
52 Week Range
10.65 - 19.05
% held by Insiders
90.05 %
% held by Institutions
11.58 %
Enterprise Value
3.38 B
Total Shares
279.97 M
Short %
16.34 %
Float Shares
28.00 M
Company Description
locked
Upcoming Catalyst
Catalyst Timeline
Dated clinical, regulatory & corporate events for MiniMed Group, Inc.
1Total events
0Upcoming
0Tier-1 (high impact)
2026 – 2026Coverage
Event history 1
Jun 29, 2026
Drug Pipeline Intelligence
C59
Pipeline Score $10.5B
Pipeline ValueValuation Signal
2
Drugs Scored3.2x
rNPV / MCap Top 86%
Small Cap (rank 128 of 906)
Percentile RankMiniMed Group, Inc. carries a moderate pipeline score (59/100), with $16.2B risk-adjusted pipeline value, led by Regular Human Insulin in Type 2 Diabetes Mellitus (Phase 2), across $161B in total addressable markets.
Showing 1 of 1 assets
| Drug | Indication | Phase | NCT ID | PTRS | rNPV | Status | Enrollment | Velocity | Design | Completion | ML Signal | Last Change |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Regular Human Insulin Small molecule | Type 2 Diabetes Mellitus | Phase 2 | NCT02415556 | 43% | $9.1B | COMPLETED | 289 | - | - | May 31, 2020 | - | May 19, 2022 |
Clinical Trial Results
| Drug Name | Indications | Phase | Date | Trial Results Summary | Title | Source |
|---|---|---|---|---|---|---|
MiniMed™ 780G system | type 1 diabetes | — | 2026-05-21 | Instinct: Time in Range 79.1 %, Hb A1c 6.7 %, Mean Sensor Glucose 137.9 mg/dL, Time in Auto Mode 90.0 %; Simplera Sync: Time in Range 80.6 %, Hb A1c 6.8 %, Mean Sensor Glucose 139.5 mg/dL, Time in Auto Mode 92.6 % Read More | New Study Showed Consistent Glycemic Outcomes Across Sensors Integrated with MiniMed 780G System Read More | |
MiniMed™ 780G system | type 1 diabetes | — | 2026-05-21 | Instinct: Time in Range 79.1 %, Hb A1c 6.7 %, Mean Sensor Glucose 137.9 mg/dL, Time in Auto Mode 90.0 %; Simplera Sync: Time in Range 80.6 %, Hb A1c 6.8 %, Mean Sensor Glucose 139.5 mg/dL, Time in Auto Mode 92.6 % Read More | New Study Showed Consistent Glycemic Outcomes Across Sensors Integrated with MiniMed 780G System Read More | |
MiniMed™ 780G system | type 1 diabetes | — | 2026-05-21 | Instinct: Time in Range 79.1 %, Hb A1c 6.7 %, Mean Sensor Glucose 137.9 mg/dL, Time in Auto Mode 90.0 %; Simplera Sync: Time in Range 80.6 %, Hb A1c 6.8 %, Mean Sensor Glucose 139.5 mg/dL, Time in Auto Mode 92.6 % Read More | New Study Showed Consistent Glycemic Outcomes Across Sensors Integrated with MiniMed 780G System Read More |
Inside Trades
YEARLY INSIDER TRANSACTIONS
Sector Avg.
INSIDERS
SOLDINSIDERS
BOUGHT
SOLDINSIDERS
BOUGHT
POSITIVE SENTIMENT Based on 22 Insiders Transactions
Hedge Funds
Shares Held
HEDGE FUNDS
SOLDHEDGE FUNDS
BOUGHT
SOLDHEDGE FUNDS
BOUGHT
POSITIVE SENTIMENT Based on 27 hedge funds in the last quarter
18 buying (3 new)·9 selling (1 exited)·2 unchanged
Hedge Funds invested in MMED
| HedgeFund Name ( 3 ) | % of Portfolio | Current MV - | Shares Owned - | Activity Avg Price $0 |
|---|---|---|---|---|
Example Capital Management | 2.5 % | 15.00 M | 250.00 K | |
Example Capital Management | 2.5 % | 15.00 M | 250.00 K | |
Example Capital Management | 2.5 % | 15.00 M | 250.00 K |
MMED Institutional Ownership Trends
Current Insider %
5.20%
—+0.00%
Current Institutional %
62.40%
—+0.00%
Total Ownership
67.60%
Insider + Institutional
Data Points
1
1 Ticker(s)
Option Chain Statistics
| Expiration | Volume | Open Interest | Implied Volatility Calls | Implied Volatility Puts | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Calls | Puts | Put-Call Ratio | Calls | Puts | Put-Call Ratio | IV | OiWaIv | VWaIv | IV | OiWaIv | VWaIv | |
| 2026-07-17 | 0 | 0.00 | 0 | 0 | - | - | - | - | - | - | ||
| 2026-07-17 | 0 | 0.00 | 0 | 0 | - | - | - | - | - | - | ||
| 2026-07-17 | 0 | 0.00 | 0 | 0 | - | - | - | - | - | - | ||
Option Chain
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last Price | Volume | Open Interest | Last Price | Volume | Open Interest | |
| No data available | ||||||
Open interest
Today's Open Interest
1.00 M
Put-Call Ratio
1.1
Put Open Interest
480.00 K
Call Open Interest
520.00 K
Open Interest Avg (30-day)
900,000
Today vs Open Interest Avg (30-day)
11.11%
Option Volume
Today's Volume
750.00 K
Put-Call Ratio
0.95
Put Volume
360.00 K
Call Volume
390.00 K
Volume Avg (30-day)
800,000
Today vs Volume Avg (30-day)
-6.25%
Company News
MMEDMiniMed appoints Alcon CEO David Endicott and Linnea Burman to its Board of Directors
MiniMed has appointed David Endicott, CEO of Alcon, and Linnea Burman to its Board of Directors, expanding the board from nine to eleven members. Endicott's experience in scaling healthcare businesses will be valuable as MiniMed continues its journey as an independent company. Burman, from Medtronic, adds further expertise to the board.
Read more →MMEDMiniMed introduceert Instinct-sensoren in Europa en biedt mensen met diabetes meer keuze met dezelfde bewezen resultaten
MiniMed has announced the commercial launch of its MiniMed 780G system integrated with Abbott's Instinct sensor in Europe. This system, along with the MiniMed Go system featuring the Instinct Go sensor, aims to provide enhanced diabetes management options. The rollout of these sensors marks a significant expansion of MiniMed's offerings in the European market.
Read more →MMEDMiniMed launches Instinct sensors in Europe giving people with diabetes more sensor choice with the same proven outcomes
MiniMed has launched the Instinct and Instinct Go sensors in Europe, integrating them with its MiniMed 780G and MiniMed Go systems. This expansion provides users with more choices for diabetes management while maintaining proven outcomes. The rollout will occur gradually, enhancing MiniMed's sensor offerings in the region.
Read more →MMEDMiniMed's Smallest App-Controlled Insulin Pump is Now Available in the U.S.
MiniMed has launched its smallest insulin pump, the MiniMed Flex™, in the U.S. This app-controlled device is designed for individuals with type 1 or insulin-requiring type 2 diabetes. It comes with the Simplera Sync™ sensor, which features a simple two-step insertion process. An additional launch with Abbott's Instinct sensor is expected later this summer.
Read more →MMEDMiniMed to Expand Sensor Portfolio with Integrated Dual Glucose-Ketone Sensors Made by Abbott
MiniMed has announced an expanded agreement with Abbott to develop dual glucose-ketone sensors that will integrate with MiniMed's smart dosing systems. This collaboration aims to enhance diabetes management by enabling early detection of rising ketones, which can help prevent diabetic ketoacidosis (DKA). The sensors are designed to be the same size as the existing Instinct sensor and will provide users with additional safety features. Regulatory updates and commercialization details are expected in the coming months.
Read more →MMEDMiniMed Delivers Strong Fourth Quarter and Full Fiscal Year 2026 Financial Results Provides Fiscal Year 2027 Outlook Continued momentum in Q4, with net sales of $837 million growing 16%
MiniMed reported strong financial results for the fourth quarter and full year of fiscal 2026, with net sales reaching $837 million, representing a 16% increase. For the first time, the company's annual net sales surpassed $3 billion, with a 14% overall growth. Positive market response is driven by the adoption of the MiniMed 780G system and successful product launches, including MiniMed Flex and MiniMed Go. Looking ahead, MiniMed projects approximately 10% organic revenue growth for fiscal year 2027, supported by new product offerings and expansion in both U.S. and international markets.
Read more →MMEDMiniMed to Showcase MiniMed Flex™ and MiniMed Go™ at the American Diabetes Association Scientific Sessions
MiniMed will showcase its latest diabetes technology, including the MiniMed Flex™ and MiniMed Go™, at the American Diabetes Association Scientific Sessions in New Orleans from June 5-8. This event marks MiniMed's first major presence as a standalone public company. Attendees will have opportunities for hands-on demonstrations and will learn about new clinical data supporting the effectiveness of these technologies.
Read more →MMEDMiniMed to Participate in Goldman Sachs 47th Annual Global Healthcare Conference
MiniMed will participate in the Goldman Sachs 47th Annual Global Healthcare Conference on June 8, 2026. The management will engage in a fireside chat, which will be accessible via a live webcast. MiniMed continues to innovate in diabetes technology, providing comprehensive solutions for diabetes management.
Read more →MMEDNew Study Showed Consistent Glycemic Outcomes Across Sensors Integrated with MiniMed 780G System
A new randomized crossover study has shown that glycemic outcomes for participants using the MiniMed™ 780G system are nearly identical with both the Simplera Sync™ and Instinct sensors. The study emphasizes the importance of the SmartGuard™ algorithm in driving these outcomes. No adverse events were reported, reinforcing the system's reliability in managing diabetes.
Read more →MMEDMiniMed to announce financial results for its fourth quarter and full fiscal year 2026
MiniMed (Nasdaq: MMED) will announce its financial results for Q4 and full fiscal year 2026 on June 3, 2026. A news release will be issued at 3:45 a.m. PDT, followed by a webcast at 5:45 a.m. PDT to discuss the results. The company continues to lead in diabetes technology, providing integrated solutions for diabetes management.
Read more →MMEDMiniMed announces closing of Initial Public Offering NORTHRIDGE, CA
MiniMed Group, Inc. announced the successful closing of its initial public offering of 28 million shares at $20 each, raising about $538 million. The IPO marks a significant milestone for the company, which remains approximately 90% owned by Medtronic. MiniMed plans to utilize the proceeds for corporate purposes and to settle intercompany debt. The offering involved several major financial institutions as bookrunners and managers, but the company faces uncertainties that could affect its future performance.
Read more →Competitive Position
How MMED ranks across every disease it competes inCompetitive Position is a premium feature
See how MMED ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trial